Pink Sheet: 世界の薬事規制と承認審査に関するニュース

How Sustainable Is England's Cancer Drugs Fund?

The Cancer Drugs Fund has improved access to oncology drugs, but if it is to remain fit for purpose it will need to evolve.

Breast Cancer Clinical Landscape and Recent Trends Whitepaper

Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

A Tale Of Two Pipelines

Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, Medtech Ins...

Transforming Cancer Treatment with Early Detection Diagnostics: Opportunities And Obstacles Webinar

Join distinguished cancer and industry experts as they explore what a shift in cancer treatment – from late stage intervention to an early detection paradigm – would mean for patient outcomes, cancer costs, technology, development, regulatory affairs, and more. Explore this new approach toward focusing on early stage cancer detection, including discussion of diagnostics in this area, such as biomarker identification, liquid biopsies, and monitoring technologies.

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

2020’s Most Significant Cancer Deals

Gain insights into the oncology deals making headlines with exclusive reporting and analysis from Scrip. Explore a snapshot view of the year’s biggest oncology deals so far, in a convenient infographic and go deeper into two major cancer deals that occurred in September with your free article pack.    

Medtech Insight: 世界の医療機器・医療技術の最新情報

Cancer Research UK: Early Diagnosis And Disease Detection Must Not Be Eclipsed By COVID-19

Coronavirus has diverted the focus of health systems away from early cancer detection, says a new report by Cancer Research UK, urging a rebalancing of priorities.

awareness, Pharma consulting: 医療用医薬品のコンサルティング

Hunting for Cancer Neoantigens : What is the best approach?

Important insights into neoantigen-based immunotherapies and which developers are leading in this growing area.

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

US FDA Approval Of Lynparza For Pancreatic Cancer Opens Door For PFS Endpoint In Disease

AstraZeneca's PARP inhibitor Lynparza becomes first US FDA-approved drug for pancreatic cancer based on progression-free survival endpoint, providing regulatory precedent for other sponsors to use that development approach; all other pancreatic cancer drugs had been approved based on an overall survival benefit.